Cassava Sciences faces lawsuit over Alzheimer's drug, accused of malicious intent to suppress criticism

From Yahoo Finance: 2025-03-26 15:49:00

Cassava Sciences faces a lawsuit from doctors and short-sellers questioning its Alzheimer’s drug simufilam. Judge allows the lawsuit to proceed, alleging Cassava knew its defamation case would fail. Short-sellers accused of harming stock price by claiming research fraud. Professor involved in fraud charges. Company accused of filing lawsuit with malicious intent to suppress criticism.

Former Cassava executives accused of suppressing scientific dialogue. Plaintiffs seek damages. Cassava shares rose dramatically in 2021, now trading at less than $2. Company to end Alzheimer’s program due to disappointing trial results. Lawsuits ongoing in Southern District of New York. Plaintiffs’ lawyer seeks accountability for defendants’ actions.

Cassava Sciences’ experimental Alzheimer’s drug simufilam faces scrutiny in a lawsuit. Short-sellers and doctors question the drug’s efficacy. Court allows lawsuit to proceed, alleging defamation lawsuit was filed with malicious intent. Former executives accused of suppressing criticism. Shares soared in 2021, now trading below $2. Company to end Alzheimer’s program.

Read more: Cassava Sciences must face malicious prosecution lawsuit over Alzheimer’s drug